TY - JOUR
T1 - The tale of TILs in breast cancer
T2 - A report from The International Immuno-Oncology Biomarker Working Group
AU - the International Immuno-Oncology Biomarker Working Group
AU - El Bairi, Khalid
AU - Haynes, Harry R.
AU - Blackley, Elizabeth
AU - Fineberg, Susan
AU - Shear, Jeffrey
AU - Turner, Sophia
AU - de Freitas, Juliana Ribeiro
AU - Sur, Daniel
AU - Amendola, Luis Claudio
AU - Gharib, Masoumeh
AU - Kallala, Amine
AU - Arun, Indu
AU - Azmoudeh-Ardalan, Farid
AU - Fujimoto, Luciana
AU - Sua, Luz F.
AU - Liu, Shi Wei
AU - Lien, Huang Chun
AU - Kirtani, Pawan
AU - Balancin, Marcelo
AU - El Attar, Hicham
AU - Guleria, Prerna
AU - Yang, Wenxian
AU - Shash, Emad
AU - Chen, I. Chun
AU - Bautista, Veronica
AU - Do Prado Moura, Jose Fernando
AU - Rapoport, Bernardo L.
AU - Castaneda, Carlos
AU - Spengler, Eunice
AU - Acosta-Haab, Gabriela
AU - Frahm, Isabel
AU - Sanchez, Joselyn
AU - Castillo, Miluska
AU - Bouchmaa, Najat
AU - Md Zin, Reena R.
AU - Shui, Ruohong
AU - Onyuma, Timothy
AU - Yang, Wentao
AU - Husain, Zaheed
AU - Willard-Gallo, Karen
AU - Coosemans, An
AU - Perez, Edith A.
AU - Provenzano, Elena
AU - Ericsson, Paula Gonzalez
AU - Richardet, Eduardo
AU - Mehrotra, Ravi
AU - Sarancone, Sandra
AU - Ehinger, Anna
AU - Rimm, David L.
AU - Saltz, Joel
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12/1
Y1 - 2021/12/1
N2 - The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC.
AB - The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC.
UR - https://www.scopus.com/pages/publications/85120908291
U2 - 10.1038/s41523-021-00346-1
DO - 10.1038/s41523-021-00346-1
M3 - Review article
AN - SCOPUS:85120908291
SN - 2374-4677
VL - 7
JO - npj Breast Cancer
JF - npj Breast Cancer
IS - 1
M1 - 150
ER -